Skip to Content
Søk Menu

HER2-Low Treatment – The Future of this Important Biomarker

Paolo Tarantino, from the Dana-Farber Cancer Institute, highlights the transformative potential of novel antibody-drug conjugates in treating HER2-positive and HER2-low breast cancer. Through recent trials, Tarantino challenges traditional assumptions about HER2 expression and demonstrates promising outcomes for HER2-low tumours.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Consecutive Mammography Screening Is the Best Way to Reduce the Risk of Premature Death from Breast Cancer

/ Sofie Pohl
Brystkreft

Recent Updates in Breast Cancer Screening – A Norwegian Perspective

/ Kaitlyn Tsuruda / Solveig Hofvind
Brystkreft
László Tabár

Mammography Screening Is the Best Way to Reduce the Risk of a Premature Death from Breast Cancer

/ László Tabár
Brystkreft Play the Video 7:11

Implementation of Early Specialized Palliative Care in an Oncologic Department

/ Katrine Rahbek Schønnemann / Sabine Ute Alice Gill
Kreft

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

/ Sofie Pohl
ASCOGI24BrystkreftGastrointestinal kreft
Hatem Azim

Using Fertility Options May be Safe for Patients with HR-positive Breast Cancer

/ Hatem Azim
BrystkreftSABCS23 Play the Video 10:10
Terry Mamounas

The Effectiveness of Regional Nodal Radiation in Patients with Breastcancer

/ Eleftherios (Terry) P. Mamounas
BrystkreftSABCS23 Play the Video 13:26

SABCS 2023: HR-Positive Breast Cancer Patients May Safely Use Fertility Options

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2023: Younger Postmenopausal Women May Safely Skip Adjuvant Radiotherapy

/ BestPractice Nordic
BrystkreftSABCS23
Back to top